Orchid Pharma Allots 4.45 Cr Shares Post Amalgamation with Dhanuka Labs
Orchid Pharma will issue 4,45,86,052 equity shares to Dhanuka Laboratories shareholders as part of an amalgamation scheme. The shares will be listed on NSE and BSE. Post-allotment, Orchid Pharma's paid-up capital increases to ₹59.89 crore.
The amalgamation and share allotment will alter the company's capital structure and ownership, which can have a medium-term impact on its financial performance and market position.
The allotment of shares and increase in paid-up capital as part of an amalgamation scheme is generally a positive development for the company, indicating consolidation and potential growth.
Orchid Pharma Limited announced on August 01, 2026, that its Board of Directors has approved the issuance and allotment of 4,45,86,052 fully paid-up equity shares of ₹10 each. These shares are to be allotted to the eligible shareholders of Dhanuka Laboratories Limited as of the record date, July 23, 2026, in accordance with the scheme of amalgamation.
The newly issued shares will be listed and traded on both the BSE Limited and the National Stock Exchange of India Limited, ranking pari passu with the existing equity shares of Orchid Pharma. Following this allotment and the cancellation of cross-holdings from Dhanuka Laboratories Limited, the paid-up share capital of Orchid Pharma has increased to ₹59,88,52,000 (₹59.89 crore), representing 5,98,85,200 equity shares of ₹10 each.
What to do with a filing like this
Orchid Pharma Limited filed this with the NSE as a statutory disclosure, categorised under amalgamation. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Orchid Pharma Limited. Read the original for the full detail.